Protagonist Therapeutics
PTGX
PTGX
316 hedge funds and large institutions have $8.3B invested in Protagonist Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 110 increasing their positions, 102 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
8% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 102
1% more funds holding
Funds holding: 313 → 316 (+3)
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
Holders
316
Holding in Top 10
10
Calls
$36.2M
Puts
$11.1M
Top Buyers
| 1 | +$213M | |
| 2 | +$73.4M | |
| 3 | +$65.6M | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$52.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$37.9M |
Top Sellers
| 1 | -$39.3M | |
| 2 | -$35.1M | |
| 3 | -$33.5M | |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$18M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.4M |